Error

The purpose of this document is to give payers a better understanding of the basics in PBM pricing models, as well as provide a brief list of questions to ask when evaluating workers’ compensation PBM vendors to help identify which will best suit their unique book of business. Read more...

As the media focuses on PBM pricing transparency, it’s important to consider all the benefits PBMs bring to the table. Read more...

Zavzpret – indicated for the acute treatment of migraine with or without aura in adults – is now available as a 10 mg nasal spray device. Read more...

According to the U.S. Food and Drug Administration (FDA), Duexis — a single-tablet combination product containing ibuprofen, a nonsteroidal anti‐inflammatory drug (NSAID), and famotidine, a histamine H2–receptor blocker — will no longer be manufactured. Read more...

Earlier this year, the American Geriatrics Society (AGS) published an update to the AGS Beers Criteria® for potentially inappropriate medication (PIM) use in older adults (65 years of age and older). Older adults are more likely to experience unwanted adverse effects and be more sensitive to certain medications. Read more...

On August 8, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important updates. Read more...

FDA approves additional over-the-counter naloxone products Read more...

The 2Q 2023 Brand-Generic Pipeline update Read more...

Extended-release Brixadi has been approved by the FDA for subcutaneous injection in patients recovering from Opioid Use Disorder as part of their treatment plan. Read more...

On June 6, the Center for Medicare & Medicaid Services (CMS) released an updated Non-Group Health Plan (NGHP) User Guide, Version 7.2, which includes important changes. Read more...